Biologic Therapy

Adverse events from disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis decline by as much as 25% after the drugs are established on the market, according to data published in Annals of the Rheumatic Diseases.

SAN DIEGO — Getting prior authorization for medications can be a struggle in allergy and asthma care, but creating templates and paying attention to detail can speed up the process and lead to more success, according to a presentation here.

ORLANDO — Patients treated with ESK-001 for moderate to severe plaque psoriasis experienced positive clinical responses through a year, according to a presentation at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

The approval of etanercept for juvenile idiopathic arthritis in 1999 heralded a new era for children with arthritis. However, despite subsequent approvals for JIA, many patients with other types of childhood arthritis remain without options.

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate to severe atopic dermatitis that topical therapies have not adequately controlled, according to a press release.

Published results showed the use of a novel bioresorbable scaffold-anchor to augment healing after rotator cuff repair may not yield clinically superior outcomes compared with a standard anchor.

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.